Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03564340
Title Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Platinum-Resistant Ovarian Cancer
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications

ovary epithelial cancer

fallopian tube cancer

peritoneum cancer

Therapies

Cemiplimab + REGN4018

REGN4018

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.